|
The use of PET/CT to detect early recurrence after resection of high-risk stage III melanoma, prior to the start of adjuvant therapy and during follow-up. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen |
|
|
Alexander Christopher Jonathan Van Akkooi |
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst) |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |